KetamineOne Capital Limited announced that it is entering into a collaborative partnership with Cognetivity Neurosciences Ltd. (Cognetivity) to study and develop assessments for depression and post-traumatic stress disorder (PTSD). In the initial stage of the partnership, Cognetivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board (IRB) approval and patient recruitment is expected to occur in early 2022.

Ketamine One's wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis. Cognetivity's Integrated Cognitive Assessment (ICA) technology has already been deployed throughout Ketamine One's network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients' cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.

The clinical studies will add to the extensive body of data validating the ICA's use as a cognitive testing tool. It has already been widely deployed in clinical care, from North America and the Middle East to clinics in the UK's National Health Service. The project will also generate novel intellectual property regarding the ICA's predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.